Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
NICE has recommended panobinostat (also known as Farydak and manufactured by Novartis) as a possible treatment for people with multiple myeloma if they have had at least two prior therapies (including bortezomib and an immunomodulatory agent).
Panobinostat is recommended only if it is provided with the discount agreed in the patient access scheme.
The decision follows public consultation on a preliminary decision not to recommend panobinostat, with the manufacturer responding to the consultation by submitting a revised economic analysis which allowed the committee to recommend the drug.
Panobinostat is a new type of oral anti-cancer treatment that works by disrupting a key mechanism which causes normal cells to turn cancerous.
According to Cancer Research UK, in 2012 there were just over 4,000 new cases of multiple myeloma in England.
Source: NICE
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.